The pioneering collaboration—devised by Cambridge, Imperial, and UCL—now opens throttle on its robust pipeline, sets up US office, explores additional collaborative relationships with leading academic researchers around the world.

A unique collaborative venture to speed development of breakthrough medical discoveries—devised by the University of Cambridge, Imperial College London, and University College London and embraced by pharmaceutical giants AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation—launches today as a £100 million biopharmaceutical company.

Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing potentially transformative treatments, has completed a £100 million financing led by Patient Square Capital and joined by Rock Springs Capital, Reimagined Ventures, and UCL Technology Fund.

The investment will support advancement of Apollo’s robust pipeline into development; expansion of the company’s operations, including establishment of a presence in the Boston, MA, area; and pursuit of new collaborations globally. Each of the joint venture founders will retain a minority stake in the company.

Conceived in 2011 by the technology transfer offices of three world-leading universities (University of Cambridge, Imperial College London, University College London), Apollo was created to speed the development of therapeutics based on cutting-edge discoveries at the three universities. In 2014, the team pitched the pioneering model to AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation, which embraced the model.

Finalised in late 2015, the joint venture launched in early 2016. In the ensuing years Apollo has sought the best science with the greatest potential to help patients. By bringing funding and industry expertise together with university breakthroughs, Apollo has developed projects to industrial standards and exceeded traditional development benchmarks of capital- and time-efficiency. Apollo now launches its next phase as a multinational company.

Established to bridge the gap between deep academic science and eventual patient benefit, the Apollo model will function well as a company. By fostering relationships with top academic scientists and leveraging insights from partners with late-stage development and commercial expertise, Apollo works to develop therapeutics that have transformative potential. It evaluates breakthrough scientific discoveries across multiple criteria, including having a compelling and testable biological hypothesis or having a differentiated mechanism or technology compared to other therapeutics in development or on the market.

To advance programs efficiently, Apollo leverages a portfolio-based model with a centralized team of drug development ‘architects’ working alongside asset-level teams of subject matter experts. Together, these teams are able to evaluate therapeutic programs rigorously, in an objective, data-driven fashion—prioritising critical experiments to de-risk programs early. The model allows the company to evaluate programmes comprehensively, while committing minimal spend until biological validation is demonstrated. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programmes currently in development.

With proceeds from this financing, Apollo plans to advance its lead therapeutic programmes into clinical development as well as identify new programmes. In addition, the company plans to expand its UK operations in the Cambridge area, as well as in the United States with a new facility in Boston/Cambridge. Apollo’s growing team will also explore additional collaborative relationships with leading academic researchers around the world.

Apollo’s unique, innovative, and hugely capital efficient model has been validated by this very significant investment. Apollo has advanced a fantastic portfolio of programmes more cost effectively and quickly than could have been achieved by traditional grant and single asset investment routes. Patient Square Capital’s partners have real knowledge and success in investing in portfolio opportunities. We are delighted they can bring their expertise to Apollo, joining us as we take science from the bench to patients.

Iain Thomas, Head of Life Sciences, Cambridge Enterprise

Apollo’s expanding pipeline of treatments across oncology, major inflammatory disorders, and rare disease is an excellent demonstration of why funding, collaboration, and the commercialisation of research at UK global research universities is so crucial for the future care of patients, the treatment of disease, and the economy.

Andy Neely, Pro-Vice-Chancellor for Enterprise and Business Relations, University of Cambridge

Make a media enquiry

If you are a journalist with a media enquiry, please contact our Press and Media Manager.